1,602,283 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Nicholson Wealth Management Group LLC

Nicholson Wealth Management Group LLC acquired a new position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,602,283 shares of the company's stock, valued at approximately $21,390,000. Perspective Therapeutics accounts for about 17.6% of Nicholson Wealth Management Group LLC's portfolio, making the stock its biggest position. Nicholson Wealth Management Group LLC owned about 2.57% of Perspective Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CATX. WealthPLAN Partners LLC acquired a new stake in Perspective Therapeutics during the second quarter worth approximately $1,695,000. Bank of New York Mellon Corp grew its holdings in Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company's stock worth $1,369,000 after purchasing an additional 93,548 shares during the period. WINTON GROUP Ltd bought a new stake in Perspective Therapeutics in the second quarter valued at $841,000. Ally Bridge Group NY LLC bought a new position in shares of Perspective Therapeutics during the 2nd quarter worth about $3,951,000. Finally, Rhumbline Advisers acquired a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at about $630,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday. They issued a "buy" rating and a $20.00 price target on the stock. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective on the stock. Oppenheimer restated an "outperform" rating and issued a $22.00 target price on shares of Perspective Therapeutics in a report on Friday, October 11th. Bank of America started coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They issued a "buy" rating and a $24.00 price objective for the company. Finally, Royal Bank of Canada cut their target price on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a research report on Friday, August 16th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $20.63.

Perspective Therapeutics Trading Down 2.9 %

Perspective Therapeutics stock traded down $0.35 during trading on Friday, hitting $11.54. The stock had a trading volume of 515,235 shares, compared to its average volume of 686,432. The company's 50 day moving average price is $13.76. Perspective Therapeutics, Inc. has a 1 year low of $2.20 and a 1 year high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. As a group, equities research analysts forecast that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.